The absolute number of circulating CD34 + cells predicts the number of hematopoietic stem cells that can be collected by apheresis

Bone Marrow Transplantation

Volumn 17, Issue 4, 1996, Pages 509-515

  Schots, R ^a,d   Van Riet, I ^a   Damiaens, S ^a   Flament, J ^b   Lacor, P ^a   Staelens, Y ^c   Steenssens, L ^b   Van Camp, B ^a   De Waele, M ^a  

^a Div of Hematology and Immunology   (Belgium)

^b Blood Transfusion Centre Jette

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

CD34 + cells; PBPC; Stem cell apheresis

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; STEM CELL; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BLOOD COMPONENT REMOVAL; BONE MARROW; CELL MOVEMENT; COLONY-FORMING UNITS ASSAY; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 0029916837     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gale RP, Henon P, Juttner C. Blood stem transplants come of age. Bone Marrow Transplant 1992; 9: 151-155.
2. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-213.
3. Gratwohl A, Hermans J. Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant 1994; 13: 5-10.
4. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
5. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
6. Siena S, Bregni M, Bonsi L et al. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors. Exp Hematol 1993; 21: 1583-1590.
7. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
8. Körbling M FLiedner TM, Holle R et al. Autologous blood stem celL (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hematopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343-349.
9. Craig JIO, Anthony RS, Stewart A et al. Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lyrnphoma. Br J Haematol 1993; 85: 210-212.
10. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections after high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
11. - hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colonystimulating factor. Blood 1989; 74: 1905-1914.
12. Rosenfeld CS, Shadduck RK, Zeigler ZR et al. Cyclophosphamide-mobilized peripheral blood stem cells in patients with lymphoid malignancies. Bone Marrow Transplant 1995; 15: 433-438.
13. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
14. Shimazaki C, Oku N, Ashihara E et al. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant 1992; 10: 341-346.
15. Pettengell R, Testa NG, Swindell R et al. Transplantation potential of hematopoietic cells into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2293-2248.
16. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony-stimulating factor. Blood 1993; 81: 3158-3163.
17. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
18. Sheridan WP, Begley CG, To LB et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105-111.
19. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
20. Brice P, Divine M, Marolleau JP et al. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas. Br J Haematol 1994; 14: 51-55.
21. Bender JG, Williams SF, Myers S et al. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation. Bone Marrow Transplant 1992; 10: 281-285.
22. Zimmerman TM, Lee WJ, Bender JG et al. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 1995; 9: 439-444.
23. - cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 1994; 13: 479-485.
24. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
25. Fritsch G, Buchinger P, Printz D. Use of flow cytometric CD34 analysis to quantify hematopoietic progenitor cells. Leuk Lymphoma 1993; 10: 443-451.
26. - cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
27. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1993; 12: 28-36.
28. Sutherland HJ, Eaves CJ, Landsdorp PM et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994; 12: 3808-3814.
29. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
30. - cells predicts the colony-forming capacity of leukapheresis products in children. Bone Marrow Transplant 1995; 15: 25-31.
31. - cells: correlation to the quantitation of circulating hematopoietic progenitor cells by in vitro colony assay. Br J Haematol 1991; 77: 453-459.
32. Dreger P, Marquardt P, Haferlach T et al. Effective mobilisation of peripheral blood progenitor cells with dexa-BEAM and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950-957.
33. - cell fraction in bone marrow and blood is not universally predictive of CFU-GM. Exp Hematol 1992; 20: 528-530.
34. Douay L, Gorin NC, Mary JY et al. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment. Exp Hematol 1986; 14: 358-365.
35. Kawano Y, Takaue Y, Watanabe T et al. Effects of progenitor cell dose and pre-leukapheresis use of human recombinant granulocyte colony stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children. Exp Hematol 1993; 21: 103-108.